

Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum

In the article “Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs”,^[1] which appeared in Volume 96, Issue 1 of *Medicine*, an acknowledgment read “This study was supported by an Inha University Hospital grant”. The statement should have read “This study was supported by an Inha University Research grant”.

Reference

- [1] Lee SH, Jin Y-J, Shin JY, et al. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. *Medicine*. 96;1:e5321.